טוען...
Targeted therapy of chronic myeloid leukemia
Inhibition of BCR-ABL with kinase inhibitors has become a well-accepted strategy for targeted therapy of Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML), and has been shown to be highly effective in controlling the disease. However, BCR-ABL kinase inhibitors do not efficiently kill leuk...
שמור ב:
| הוצא לאור ב: | Biochem Pharmacol |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2010
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4440481/ https://ncbi.nlm.nih.gov/pubmed/20470758 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2010.05.001 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|